Adipose Stromal Cells from Visceral and Subcutaneous Fat Facilitate Migration of Ovarian Cancer Cells via IL-6/JAK2/STAT3 Pathway.
- Author:
Boyun KIM
1
;
Hee Seung KIM
;
Soochi KIM
;
Guy HAEGEMAN
;
Benjamin K TSANG
;
Danny N DHANASEKARAN
;
Yong Sang SONG
Author Information
- Publication Type:Original Article
- Keywords: Ovarian neoplasms; Adipose tissue; Interleukin-6; Cell movement; Adipose stromal cells
- MeSH: Adipose Tissue; Antibodies, Neutralizing; Ascites; Blotting, Western; Cell Line; Cell Movement; Culture Media, Conditioned; Humans; Inflammation; Interleukin-6; Intra-Abdominal Fat; Metabolism; Neoplasm Metastasis; Ovarian Neoplasms*; RNA, Small Interfering; Stromal Cells*; Subcutaneous Fat*
- From:Cancer Research and Treatment 2017;49(2):338-349
- CountryRepublic of Korea
- Language:English
- Abstract: PURPOSE: Adipose stromal cells (ASCs) play an important regulatory role in cancer progression and metastasis by regulating systemic inflammation and tissue metabolism. This study examined whether visceral and subcutaneous ASCs (V- and S-ASCs) facilitate the growth and migration of ovarian cancer cells. MATERIALS AND METHODS: CD45– and CD31– double-negative ASCs were isolated from the subcutaneous and visceral fat using magnetic-activated cell sorting. Ovarian cancer cells were cultured in conditioned media (CM) obtained from ASCs to determine the cancer-promoting effects of ASCs. A 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay, Boyden chamber assay, and western blotting were performed to determine the proliferative activity, migration ability, and activation of the JAK2/STAT3 pathway, respectively. RESULTS: CM from ASCs enhanced the migration of the ovarian cancer line, SKOV3, via activation of the JAK2/STAT3 signaling pathway. Interestingly, in response to ASC-CM, the ascites cells derived from an ovarian cancer patient showed an increase in growth and migration. The migration of ovarian cancer cells was suppressed by blocking the activation of JAK2 and STAT3 using a neutralizing antibody against interleukin 6, small molecular inhibitors (e.g., WP1066 and TG101348), and silencing of STAT3 using siRNA. Anatomical differences between S- and V-ASCs did not affect the growth and migration of the ovarian cancer cell line and ascites cells from the ovarian cancer patients. CONCLUSION: ASCs may regulate the progression of ovarian cancer, and possibly provide a potential target for anticancer therapy.
